<DOC>
	<DOCNO>NCT02554396</DOCNO>
	<brief_summary>This one-day , randomize , double-masked , single-center evaluation efficacy safety PRX-100 ophthalmic solution compare placebo 20 subject ( randomized 4:1 , PRX-100 : placebo ) evaluate safety PRX-100 magnitude duration effect improve near-vision acuity .</brief_summary>
	<brief_title>Evaluation Efficacy Safety PRX-100 Treatment Early Moderate Presbyopia</brief_title>
	<detailed_description />
	<mesh_term>Presbyopia</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1. 4559 year age either sex race ethnicity ; 2. able willing provide write informed consent sign HIPAA form prior study procedure perform ; 3. able willing follow instruction attend study visit ; 4. negative urine pregnancy test Visit 1 , female childbearing potential ( experienced menarche surgically sterilize [ bilateral tubal ligation , hysterectomy bilateral oophorectomy ] postmenopausal [ 12 month last menses ] ) must use adequate birth control throughout study period . Adequate birth control define hormonal oral , implantable , injectable , transdermal contraceptive ; mechanical spermicide conjunction barrier condom diaphragm ; intrauterine device ( IUD ) ; surgical sterilization partner . For nonsexually active female , abstinence may regard adequate method birth control ; 5. early moderate presbyope 6. able willing avoid disallow medication ( ) appropriate washout period study without significant risk subject ( see exclusion 15 ) . 1. known contraindication sensitivity use study medication ( ) component ; 2. active ocular infection ( bacterial , viral fungal ) , positive history ocular herpetic infection , preauricular lymphadenopathy , ongoing , active ocular inflammation ( e.g . moderate severe blepharitis , allergic conjunctivitis , peripheral ulcerative keratitis , scleritis , uveitis ) either eye . Mild dry eye control artificial tear mild blepharitis control lid scrub allow ; 3. surgical intervention ( ocular systemic ) within 6 month prior Visit 1 , plan surgical intervention within 30 day thereafter ; 4. refractive surgery past ; 5. dry eye history define either current use Restasis® , past history insertion punctual plug , daily use artificial tear one drop per day ; 6. know history retinal detachment , diabetic retinopathy , progressive retinal disease ; 7. intraocular pressure le 5 mmHg great 22 mmHg , type intraocular hypertension type glaucoma topical treatment Visit 1 ; 8. redgreen color blindness confirm Ishihara test baseline procedure ; 9. inability refuse discontinue contact lens wear 7 day prior study visit study visit ; 10. use investigational drug device within 30 day start study concurrently enrol another investigational drug device study ; 11. female childbearing potential currently pregnant , nurse planning pregnancy ; test positive urine pregnancy test Visit 1 ; refuse use adequate method contraception duration study ; 12. condition situation , Investigator 's opinion , may put subject increase risk , confound study data , interfere significantly subject 's study participation , include limited unstable : cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease ; 13. use follow disallow medication 2 week ( 14 day ) prior Visit 1 study : narcotic ( opiate class ) pain medication ( e.g . codeine , oxycontin , Vicodin® , Tramadol® ) bladder medication ( e.g . urecholine , bethanechol® ) antipsychotic antidepressant anticholinergic ( e.g . atropine , belladonna , benztropine , dicyclomine , donepezil , hyoscyamine , propantheline , scopolamine , trihexphenidyl dry mouth ( e.g . salagen® ) , Evoxac® ) antihistamines decongestant artificial tear use 1 drop per day diagnostic medication require protocol allow ; 14. report recreational drug use ( e.g . marijuana , methadone , heroin , cocaine ) .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>ophthalmology</keyword>
	<keyword>vision</keyword>
	<keyword>ocular</keyword>
</DOC>